Belite Bio Eyes FDA Nod After Stargardt Drug Success, $402M Raise

SAN DIEGO, CA – March 02, 2026 – Clinical-stage drug developer Belite Bio is poised to transform the treatment landscape for a rare, inherited form of blindness after announcing a string of pivotal successes, including positive topline results for its lead drug candidate, tinlarebant. The company is now on a clear path to seek regulatory approval for what could become the first-ever treatment for Stargardt disease type 1 (STGD1).

In a corporate update accompanying its preliminary 2025 financial results, Belite Bio confirmed that its global Phase 3 DRAGON trial met its primary endpoint, demonstrating that the oral, once-daily medication significantly slows the progression of the debilitating eye disease in adolescents. Bolstered by these results and a recently completed $402 million public offering, the company is preparing for a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in the second quarter of 2026.

“2025 marked a defining year for Belite, highlighted by positive topline results from our pivotal Phase 3 DRAGON trial, establishing tinlarebant as a potential first-in-class therapy for Stargardt disease,” said Dr. Tom Lin, Chairman and CEO of Belite Bio, in a statement. “We remain on track... as we advance toward our goal of bringing the first approved treatment for Stargardt disease to people living with this debilitating disease.”

A Breakthrough for an Untreatable Disease

Stargardt disease is the most common inherited macular dystrophy, affecting an estimated 30,000 to 50,000 people in the United States. Caused primarily by mutations in the ABCA4 gene, the condition leads to the accumulation of toxic vitamin A byproducts, known as bisretinoids, in the retina. This toxicity results in the progressive death of photoreceptor cells, causing irreversible vision loss that typically begins in childhood or young adulthood. To date, patients have had no approved therapeutic options.

Belite Bio’s pivotal, 24-month DRAGON trial enrolled 104 adolescent patients who were randomized to receive either tinlarebant or a placebo. The trial’s primary endpoint was the rate of growth of macular lesions, a key marker of disease progression. The results were statistically significant and clinically meaningful, showing that tinlarebant reduced the growth rate of these lesions by 35.7% compared to placebo. The company reported a p-value of 0.0033, well below the threshold for statistical significance.

Tinlarebant works by a novel mechanism. It is a retinol binding protein 4 (RBP4) antagonist, which means it reduces the amount of RBP4 in the blood. This, in turn, decreases the delivery of vitamin A to the eye, thereby limiting the formation of the toxic bisretinoids that drive Stargardt disease. The approach is designed to be targeted, slowing disease progression in the eye without disrupting the essential functions of vitamin A in other parts of the body. The drug demonstrated a favorable safety profile in the trial, consistent with previous studies.

Paving the Path to Market with a Fortified War Chest

The promising clinical data is backed by a formidable financial strategy that positions Belite Bio for the costly transition from a research-focused entity to a commercial-stage company. The successful completion of a $402 million underwritten public offering has substantially strengthened its balance sheet. As of December 31, 2025, the company reported cash and cash equivalents of $352.9 million, a dramatic increase from $31.7 million at the end of 2024.

This capital infusion is critical, as the company's expenditures are rising in line with its late-stage development activities. Research and development expenses for 2025 climbed to $45.4 million from $29.9 million in 2024, driven by costs associated with its clinical trials. The company’s GAAP net loss for the year widened to $77.6 million. This increased burn rate is expected for a biotech advancing multiple pivotal trials and preparing for a potential product launch.

The proceeds are earmarked to support commercialization preparations, ongoing clinical development, and pipeline expansion. Belite Bio’s regulatory path is further smoothed by several key designations from the FDA, including Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations. These are intended to expedite the review of drugs for serious conditions with high unmet needs. The Rare Pediatric Disease Designation also makes Belite Bio eligible to receive a Priority Review Voucher upon approval, a valuable asset that can be used to accelerate the review of another drug or be sold to another company.

Navigating a Crowded and Competitive Field

While tinlarebant is the clear frontrunner, the significant unmet need in Stargardt disease has attracted a number of competitors. The field includes a variety of therapeutic approaches, from gene therapies aiming to correct the underlying genetic defect to other small molecules.

Companies like Alkeus Pharmaceuticals are developing a modified form of vitamin A to reduce toxin formation, while others, including Nanoscope Therapeutics and AAVantgarde Bio, are advancing gene therapies. These gene-based treatments, while potentially curative, often involve more complex administration, such as surgical procedures, compared to tinlarebant's convenient oral, once-daily pill.

Tinlarebant’s primary advantages are its advanced stage of development—being the first to report positive Phase 3 data—and its patient-friendly oral delivery. This combination could give it a significant first-mover advantage and a strong competitive edge in the market, should it gain approval.

Beyond Stargardt: A Vision for Broader Applications

Belite Bio's ambitions for tinlarebant extend beyond Stargardt disease. The company is also evaluating the drug in a pivotal Phase 3 trial, known as PHOENIX, for the treatment of Geographic Atrophy (GA). GA is the advanced form of dry age-related macular degeneration (AMD) and a leading cause of blindness in the elderly, representing a vastly larger patient population than Stargardt disease.

The scientific rationale is that the accumulation of toxic bisretinoids also plays a role in the progression of GA. If tinlarebant's mechanism proves effective in this second, more common indication, it would represent a monumental breakthrough. The company has already completed enrollment for the PHOENIX trial with 530 subjects and expects to conduct an interim analysis.

Meanwhile, the company continues to advance its Stargardt program with the DRAGON II trial, a Phase 2/3 study that has already enrolled 72 subjects across Japan, the U.S., and the U.K. This trial is designed to support a future NDA submission in Japan and further solidify the drug's clinical profile. Success in the GA indication would not only validate the drug's mechanism across different diseases but also firmly establish Belite Bio as a major contender in the broader ophthalmology market.